CAM
RAPT

Cormorant Asset Management’s RAPT Therapeutics RAPT Stock Holding History

Cormorant Asset Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,000
Closed -$316K – 47
2024
Q4 		$316K Sell
25,000
-37,094
-60% -$471K 0.02% 48
2024
Q3 		$998K Hold
62,094
– – 0.05% 45
2024
Q2 		$1.52M Hold
62,094
– – 0.09% 49
2024
Q1 		$4.46M Hold
62,094
– – 0.2% 55
2023
Q4 		$12.3M Buy
62,094
+21,469
+53% +$2.66M 0.59% 37
2023
Q3 		$5.4M Hold
40,625
– – 0.32% 38
2023
Q2 		$6.08M Sell
40,625
-40,625
-50% -$6.33M 0.34% 47
2023
Q1 		$11.9M Buy
+81,250
New +$16.4M 0.79% 34

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Cormorant Asset Management's RAPT Position: Q1 2025 in Review

Cormorant Asset Management sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 25,000 shares — an estimated $316K sold.

Cormorant Asset Management first reported a position in RAPT in Q1 2023 and held it in 8 quarters. The position peaked at $12.3M in Q4 2023. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

  • Cormorant Asset Management reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 25,000 RAPT Therapeutics shares in Q1 2025, an estimated $316K.
  • Cormorant Asset Management first reported a position in RAPT Therapeutics in Q1 2023 and held it in 8 quarters.
  • Cormorant Asset Management's RAPT Therapeutics position peaked at $12.3M in Q4 2023.
  • 92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.